RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia

New insights into pulmonary hypertension from recent trials

Chair(s): L. Rubin (New York, United States of America), O. Sitbon (Le Kremlin-Bicêtre, France)

Session type: Oral Presentation

S. Nathan (Falls Church, United States of America)

EVENTS HOME

Previous presentation

Next presentation

Session content

Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study

M. Hoeper (Hannover, Germany)

Replay

Poster

Abstract

Slides

Pulmonary arterial hypertension-related morbidity is prognostic for survival: insights from the SERAPHIN and GRIPHON studies

M. Hoeper (Hannover, Germany)

Replay

Abstract

Slides

Iron carboxymaltose improves exercise tolerance and right heart strain in patients with PAH and iron deficiency: A long-term pilot study

T. Kramer (Köln, Germany)

Replay

Abstract

Slides

The ARROW Study: A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study of Selonsertib in Subjects with Pulmonary Arterial Hypertension

G. Brooks (Foster City, United States of America)

Replay

Abstract

Slides

Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study

G. Simonneau (Le Kremlin-Bicêtre, France)

Replay

Abstract

Slides

RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia

S. Nathan (Falls Church, United States of America)

Replay

Poster

Abstract

Slides

Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL

R. Benza (Pittsburgh, United States of America)

Abstract

Slides

The ERS International Congress 2017, Milan

#{title}